---
title: "VK2735 in Chronic weight management: VENTURE-Oral dosing"
description: "Formulary evidence on VK2735 in Chronic weight management: VENTURE-Oral dosing. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 57 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence/venture-oral-dosing"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: VENTURE-Oral dosing

<a id="heading-3.1.6"></a>

## 3.1.6 VENTURE-Oral Dosing

<a id="heading-3.1.6.1"></a>

### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

#### Objective stated in the congress poster

> “To evaluate the safety, tolerability, and efficacy of various doses of oral VK2735 on weight reduction in adults with obesity or overweight with ≥1 weight-related comorbidity”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.1-2"></a>

#### Registry statement of the study aims

> “This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.”
> “To measure the efficacy of oral VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.1-3"></a>

#### Purpose of the exploratory maintenance cohort

> “The Venture Oral Study also included an exploratory dosing arm designed to evaluate the transition from a high daily dose to a low maintenance dose. This arm was intended to help us understand the potential to transition subjects to low doses following induction of weight loss with either the injectable or high-dose oral formulations.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="heading-3.1.6.2"></a>

### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

#### Registry study dates

| Milestone | Registry entry |
| --- | --- |
| Study start (actual) | “2024-12-18” |
| Primary completion (actual) | “2025-06-24” |
| Study completion (actual) | “2025-08-15” |
| First posted | “2025-02-14” |
| Last update posted | “2025-10-06” |

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.2-2"></a>

#### Study sites in the United States

| Site | City | State |
| --- | --- | --- |
| Site 111 | “Peoria” | “Arizona” |
| Site 105 | “Lake Forest” | “California” |
| Site 101 | “Clearwater” | “Florida” |
| Site 108 | “Largo” | “Florida” |
| Site 107 | “Ocoee” | “Florida” |
| Site 102 | “Port Orange” | “Florida” |
| Site 100 | “Indianapolis” | “Indiana” |
| Site 110 | “Louisville” | “Kentucky” |
| Site 114 | “Marrero” | “Louisiana” |
| Site 109 | “City of Saint Peters” | “Missouri” |
| Site 112 | “Kansas City” | “Missouri” |
| Site 113 | “Butte” | “Montana” |
| Site 103 | “Knoxville” | “Tennessee” |
| Site 104 | “Austin” | “Texas” |
| Site 106 | “San Antonio” | “Texas” |

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.2-3"></a>

#### Trial initiation announcement

> “SAN DIEGO, Jan. 8, 2025 /PRNewswire/”
> “today announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735”

Source: [Viking Therapeutics VENTURE-Oral initiation release (2025)](https://ir.vikingtherapeutics.com/2025-01-08-Viking-Therapeutics-Announces-Initiation-of-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.2-4"></a>

#### Enrollment completion announcement

> “SAN DIEGO, March 26, 2025 /PRNewswire/”
> “today announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735”

Source: [Viking Therapeutics VENTURE-Oral enrollment release (2025)](https://ir.vikingtherapeutics.com/2025-03-26-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.2-5"></a>

#### Topline results announcement

> “SAN DIEGO, Aug. 19, 2025 /PRNewswire/”
> “today announced positive top-line results from the company's Phase 2 clinical trial of the oral tablet formulation of VK2735”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.2-6"></a>

#### Congress presentation of the results

> “Istanbul, Turkiye • May 12–15, 2026”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

> “Publication Number: PO4.260”
> “Date/Time: On display May 12-15, with poster networking session on May 14 from 18 – 19:15 Turkish Time”

Source: [Viking Therapeutics ECO 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-05-12-Viking-Therapeutics-Presents-Data-from-its-13-Week-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-at-European-Congress-on-Obesity-ECO-2026)

<a id="heading-3.1.6.3"></a>

### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

#### Randomized, double-blind, placebo-controlled multicenter design

> “The Phase 2 VENTURE-Oral Dosing Trial was a randomized, double-blind, placebo-controlled multicenter study designed to evaluate the safety, tolerability, pharmacokinetics and weight loss efficacy of VK2735 dosed as an oral tablet once daily for 13 weeks.”
> “Enrolled patients were evenly randomized to one of six dosing arms or placebo.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.3-2"></a>

#### Registry design and masking

| Design element | Registry entry |
| --- | --- |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Triple” |
| Primary purpose | “Treatment” |

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.3-3"></a>

#### Seven-arm randomization with screening and follow-up periods

> “Randomization 1:1:1:1:1:1:1”
> “All groups: Advised to exercise and reduce caloric intake”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

> “Multicenter, parallel cohort, 13-week trial in obese subjects; Double-blind treatment, 13 weeks of daily dosing”
> “Maintenance (n=40)”
> “6 wk follow-up”
> “4 wk screening”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.6.3-4"></a>

#### Phase designation in company documents

> “VENTURE Oral Dosing Phase 2a Study Design”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “The Phase 2a VENTURE-Oral Dosing study results provide important data to inform the design of our upcoming oral Phase 3 registration studies.”

Source: [Viking Therapeutics ECO 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-05-12-Viking-Therapeutics-Presents-Data-from-its-13-Week-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-at-European-Congress-on-Obesity-ECO-2026)

<a id="heading-3.1.6.4"></a>

### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

#### Inclusion criteria

> “Age ≥18 years of age at the time of signing the informed consent.”
> “Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI <50 kg/m2”
> “Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.4-2"></a>

#### Exclusion criteria

> “Self-reported body weight change of 5% or more within 3 months of screening”
> “Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational)”
> “Current or past diagnosis of chronic pancreatitis”
> “Calcitonin ≥50 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)”
> “Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening”
> “Any prescription or over-the-counter medications intended for weight loss within 6 months of screening”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.4-3"></a>

#### Body mass index requirement in company documents

> “All enrolled participants were required to have baseline BMI ≥30 kg/m2 or BMI≥27 kg/m2 with at least one weight-related comorbid condition.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “Baseline BMI ≥30 in all subjects.”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="heading-3.1.6.5"></a>

### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

#### Once-daily oral tablet dose arms and titration schedules

| Arm | Titration schedule |
| --- | --- |
| 15 mg | “15 mg cohort = 15 mg x 13 weeks” |
| 30 mg | “30 mg cohort = 30 mg x 13 weeks” |
| 60 mg | “60 mg cohort = 30 mg x 2 weeks, 60 mg x 11 weeks” |
| 90 mg | “90 mg cohort = 30 mg x 2 weeks, 60 mg x 2 weeks, 90 mg x 9 weeks” |
| 120 mg | “120 mg cohort = 30 mg x 2 weeks, 60 mg x 2 weeks, 90 mg x 2 weeks, 120 mg x 7 weeks” |
| Exploratory maintenance cohort | “30 mg x 1 week, 60 mg x 1 week, 90 mg x 4 weeks, 30 mg x 7 weeks” |

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.5-2"></a>

#### Exploratory maintenance cohort: 90 mg induction followed by 30 mg daily

> “In this treatment group, participants were rapidly titrated to 90 mg daily doses. After 4 weeks of daily dosing at 90 mg, participants were down-titrated to 30 mg daily doses and maintained at 30 mg daily for 7 weeks.”
> “Transition to 30 mg occurred following completion of Week 6 dosing.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.5-3"></a>

#### Placebo and registry arm descriptions

> “Matching Placebo to VK2735”
> “VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily”
> “Active Assignment (Dose #6)”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.5-4"></a>

#### Titration in two-week steps starting at 30 mg

> “We, based on the phase I data, we had used two-week titration blocks, and we started at 30 mg.”

Source: [Viking Therapeutics Jefferies London conference transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/412049-jefferies-london-healthcare-conference-2025/)

<a id="topic-3.1.6.5-5"></a>

#### Tablet strength, pill count, and fasting administration

> “These patients were dosed after an overnight fast. We have not done a food effect study, so we don't know if a fast will be required.”
> “As far as the pill counts, these were 30 mg tablets, and people took four 30s at the top dose.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

> “What I didn't mention is that the VENTURE-Oral study, everybody took four tablets, even the placebos.”

Source: [Viking Therapeutics Jefferies London conference transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/412049-jefferies-london-healthcare-conference-2025/)

<a id="heading-3.1.6.6"></a>

### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

#### 3.1.6.6.1 Rationale for Using Percent Change in Body Weight as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

##### Primary endpoint: percent change in body weight at week 13

> “Percent (relative) change from baseline in body weight after 13 weeks of treatment”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

> “The primary endpoint of the study was the percent change in body weight from baseline to Week 13 among patients treated with oral VK2735 versus placebo in the modified intent-to-treat (mITT) population”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.6.1-2"></a>

##### Secondary endpoints: proportions reaching 5% and 10% weight loss

> “Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13. Observed and change from baseline in body weight (kg) after 13 weeks of treatment”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-3.1.6.6.1-3"></a>

##### Safety outcomes

> “Incidence of Treatment-emergent Adverse Events, incidence of Treatment-Emergent Serious Adverse Events and incidence of Adverse Events of Special Interest”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

> “Severity was rated by investigators using the Common Terminology Criteria (CTC) for Adverse Events 1 to 5 grading scale.”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.6.1-4"></a>

##### Pharmacokinetic outcomes not reported

> “We don't have any PK data from the study.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

> “With respect to the additional data, we've not received the final PK report from the oral dosing study, the VENTURE-Oral Dosing Study.”

Source: [Viking Therapeutics third quarter 2025 earnings call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/366279-q3-2025/)

<a id="topic-3.1.6.6.1-5"></a>

##### Clinical relevance of weight reduction cited by the investigators

> “The clinical benefits of 5% to >10% weight reduction have been demonstrated”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

Additional sources: [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

<a id="heading-3.1.6.7"></a>

### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

#### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

##### Planned enrollment

> “The trial will enroll approximately 280 adults who are obese (BMI ≥30 kg/m2), or adults who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.”

Source: [Viking Therapeutics VENTURE-Oral initiation release (2025)](https://ir.vikingtherapeutics.com/2025-01-08-Viking-Therapeutics-Announces-Initiation-of-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.7.1-2"></a>

##### Actual enrollment

> “The trial enrolled 280 adults who are obese (BMI ≥30 kg/m2), or adults who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.7.1-3"></a>

##### Participants analyzed by arm

| Arm | Efficacy population | Safety population |
| --- | --- | --- |
| Placebo | “(n=40)” | “(n=40)” |
| VK2735 15 mg | “(n=40)” | “(n=40)” |
| VK2735 30 mg | “(n=40)” | “(n=40)” |
| VK2735 60 mg | “(n=38)” | “(n=40)” |
| VK2735 90 mg | “(n=39)” | “(n=40)” |
| VK2735 120 mg | “(n=39)” | “(n=40)” |
| Exploratory maintenance cohort | “Efficacy population (n=39)” | Not reported |

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="heading-3.1.6.7.2"></a>

#### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

##### Efficacy and safety populations

> “Efficacy population, includes all randomized patients who received at least one dose of study drug and had a valid baseline and post-baseline body weight assessment.”
> “Safety population, includes all randomized subjects who received at least one dose of study drug.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “Study safety population, defined as all patients who were randomized and received at least one dose of study drug or placebo.”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.6.7.2-2"></a>

##### Modified intention-to-treat population in the poster

> “mITT, modified intention-to-treat”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.7.2-3"></a>

##### Statistical models for the primary and key secondary endpoints

> “Least squares mean.”
> “Two-sided t-test using mixed model for repeated measures.”
> “Logistic regression model with treatment as factor and baseline weight as covariate.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “p-value for the comparison of the LS Mean Difference from baseline between treatment and placebo.”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.6.7.2-4"></a>

##### Sample size calculation and multiplicity control

No evidence found.

<a id="topic-3.1.6.7.2-5"></a>

##### Estimand and handling of missing data

No evidence found.

<a id="heading-3.1.6.8"></a>

### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

#### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

##### Treatment and study discontinuation by dose

| Category | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Participants | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” |
| Discontinued treatment early, n (%) | “7 (18)” | “8 (20)” | “8 (20)” | “11 (28)” | “10 (25)” | “15 (38)” |
| TEAE leading to treatment discontinuation, n (%) | “5 (13)” | “2 (5)” | “5 (13)” | “7 (18)” | “8 (20)” | “12 (30)” |
| Drug-related TEAE leading to treatment discontinuation, n (%) | “3 (8)” | “1 (3)” | “5 (13)” | “6 (15)” | “8 (20)” | “11 (28)” |
| Discontinued study early, n (%) | “2 (5)” | “4 (10)” | “5 (13)” | “5 (13)” | “3 (8)” | “5 (13)” |
| TEAE leading to study discontinuation, n (%) | “1 (3)” | “0” | “1 (3)” | “0” | “1 (3)” | “0” |
| Drug-related TEAE leading to study discontinuation, n (%) | “1 (3)” | “0” | “1 (3)” | “0” | “1 (3)” | “0” |

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.8.1-2"></a>

##### Pooled discontinuation rates, VK2735 versus placebo

> “During the study 13% of participants receiving placebo discontinued treatment due to an adverse event, compared with 20% of participants receiving VK2735 treatment. The most common reasons for treatment discontinuation were gastrointestinal (GI)-related adverse events. Overall treatment discontinuation rates were 18% among placebo subjects compared with 28% among VK2735 subjects.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “Treatment and study discontinuation rates among VK2735 treated cohorts were generally dose-dependent, with higher dose cohorts demonstrating slightly higher rates than placebo. Approximately 11% of VK2735 treated subjects discontinued the study early, compared with approximately 5% for placebo.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="topic-3.1.6.8.1-3"></a>

##### Distinction between treatment discontinuation and study discontinuation

> “Participants could discontinue treatment and remain in study.”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

> “Discontinuation from the study is people drop out of the study completely and don't return to their clinical sites for any follow-up visits.”
> “Discontinuing treatment means you've stopped taking the therapy but continued to return to the site for your scheduled clinic visits, but you're not taking the treatment anymore.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="topic-3.1.6.8.1-4"></a>

##### Reasons for discontinuation

> “Treatment discontinuations generally dose-dependent; may be related to titration rate”
> “Most common TEAEs leading to discontinuation of drug: nausea, vomiting, constipation”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “Discontinuation of treatment was primarily driven by GI adverse events, and that was primarily driven by nausea rates across all arms.”
> “Withdrawal of consent is probably the highest reason for discontinuation.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="topic-3.1.6.8.1-5"></a>

##### Exploratory maintenance cohort discontinuation

> “As far as discontinuations, they were similar between the two arms.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="heading-3.1.6.8.2"></a>

#### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

##### Baseline characteristics by arm, safety population

| Characteristic | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Participants | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” |
| Age, mean years | “51” | “54” | “53” | “49” | “52” | “50” |
| Sex, % male:female | “30:70” | “20:80” | “45:55” | “15:85” | “32:68” | “28:72” |
| White, % | “85” | “80” | “73” | “68” | “88” | “83” |
| Non-Hispanic, % | “70” | “78” | “80” | “85” | “75” | “73” |
| Weight, mean kg | “105” | “99” | “103” | “103” | “103” | “102” |
| BMI, mean kg/m2 | “38” | “37” | “35” | “37” | “37” | “37” |
| Prediabetes, % | “53” | “45” | “60” | “38” | “68” | “63” |

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.8.2-2"></a>

##### Overall population: age, sex, race, and prediabetes definition

> “Majority of participants were non-Hispanic, White, female”
> “Mean age was 51 years for entire population, 83% of participants were <65 years”
> “Prediabetes defined as fasting plasma glucose (FPG) 100 – 125 mg/dL or hemoglobin A1c (HbA1c) 5.7 – 6.4%.”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

> “with an average BMI of 37 and average age of 51 years”
> “there was a high prevalence of cardiometabolic risk factors, including pre-diabetes (54%). Across all dose cohorts, the male-to-female ratio ranged from 15:85 to 45:55.”

Source: [Viking Therapeutics ECO 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-05-12-Viking-Therapeutics-Presents-Data-from-its-13-Week-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-at-European-Congress-on-Obesity-ECO-2026)

<a id="topic-3.1.6.8.2-3"></a>

##### Mean baseline body weight by arm, efficacy population

| Arm | Mean baseline body weight |
| --- | --- |
| Placebo | “105.2 kg” |
| VK2735 15 mg | “99.0 kg” |
| VK2735 30 mg | “102.9 kg” |
| VK2735 60 mg | “102.8 kg” |
| VK2735 90 mg | “103.4 kg” |
| VK2735 120 mg | “101.9 kg” |
| Exploratory maintenance cohort | “102.8 kg” |

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="heading-3.1.6.8.3"></a>

#### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

##### Primary and key secondary endpoints at week 13 by dose

| Measure | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Participants, efficacy population | “(n=40)” | “(n=40)” | “(n=40)” | “(n=38)” | “(n=39)” | “(n=39)” |
| Mean change from baseline body weight, least squares mean | “-1.3 kg” | “-2.2 kg” | “-7.1 kg” | “-8.8 kg” | “-11.5 kg” | “-12.1 kg” |
| Mean percent change from baseline, least squares mean | “-1.3 %” | “-2.3 %” | “-7.0 %” | “-8.7 %” | “-11.1 %” | “-12.2 %” |
| p-value versus baseline | “-” | “0.0057” | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |
| Placebo-adjusted mean percent change from baseline | “-” | “-1.0 %” | “-5.7 %” | “-7.4 %” | “-9.8 %” | “-10.9 %” |
| p-value versus placebo, percent change | “-” | “-” | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |
| Percent reporting at least 10% weight loss | “5 %” | “8 %” | “35 %” | “40 %” | “59 %” | “80 %” |
| p-value versus placebo, at least 10% weight loss | “-” | “-” | “<0.01” | “0.0017” | “< 0.0001” | “<0.0001” |

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.8.3-2"></a>

##### Proportions achieving at least 5% and at least 10% weight loss

> “All doses of VK2735 >15 mg also demonstrated statistically significant differences relative to placebo on the key secondary endpoint assessing the proportion of subjects demonstrating at least 5% and 10% weight loss. Up to 97% of subjects in the VK2735 treatment groups achieved ≥5% weight loss, compared with 10% for placebo, and up to 80% of subjects in VK2735 treatment groups achieved ≥10% weight loss, compared with 5% for placebo.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.8.3-3"></a>

##### Time course of weight loss from week 1 through week 13

> “Reductions in body weight were progressive at all doses through the course of the study, with no plateau observed for weight loss at 13 weeks. Statistically significant differences compared to both baseline and placebo were observed for all doses >15 mg starting at Week 1 and continuing throughout the 13-week treatment period.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “All doses >15 mg resulted in significantly greater weight loss than placebo starting in Week 1 and maintained through Week 13”
> “Primary end point was significantly improved versus baseline for all oral VK2735 doses at Week 13”
> “It was significantly improved versus placebo for all doses >15 mg”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.8.3-4"></a>

##### Exploratory maintenance cohort: weight change after transition from 90 mg to 30 mg

| Measure | Week 3, 90 mg | Week 6, 90 mg | Week 9, 30 mg | Week 13, 30 mg |
| --- | --- | --- | --- | --- |
| Mean change from baseline body weight, least squares mean | “-5.2 kg” | “-8.1 kg” | “-8.8 kg” | “-9.1kg” |
| Mean percent change from baseline, least squares mean | “-5.1 %” | “-8.1 %” | “-8.8 %” | “-9.2 %” |
| Placebo-adjusted mean percent change from baseline | “-4.3 %” | “-6.7 %” | “-7.6 %” | “-7.9 %” |
| p-value versus placebo | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “Weight loss in this treatment group was shown to be rapid and progressive through the 90 mg treatment period and was maintained following the transition to 30 mg daily doses. The observed results suggest that effective weight maintenance may also be achieved at doses <30 mg.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “Down-titration from 90mg to 30mg produced continued gradual weight loss through Week 13”
> “90 mg/30 mg cohort (red line) = 30 mg x 1 wk, 60 mg x 1 wk, 90 mg x 4 wks, 30 mg x 7 wks”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.6.8.3-5"></a>

##### Weight change at week 16, three weeks after the last dose

| Arm | Week 16 change from baseline, least squares mean |
| --- | --- |
| Placebo | “-1.4%” |
| VK2735 30 mg | “-6.7%” |
| VK2735 30/60 mg (60 mg arm) | “-8.2%” |
| VK2735 30/60/90 mg (90 mg arm) | “-10.3%” |

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “Majority of weight loss maintained for an additional 3 weeks following completion of dosing”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.6.8.3-6"></a>

##### Dose range selected for further development

> “Potential Future Dose Range ~20 mg to ~60 mg”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “The study achieved an important development goal, which was to identify a suitable dosing range moving forward.”

Source: [Viking Therapeutics third quarter 2025 earnings call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/366279-q3-2025/)

<a id="heading-3.1.6.8.4"></a>

#### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

#### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

##### Treatment-emergent adverse events by dose

| Category | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Participants | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” |
| TEAEs, n (%) | “34 (85)” | “35 (88)” | “33 (83)” | “33 (83)” | “37 (93)” | “36 (90)” |
| Treatment-related TEAEs, n (%) | “27 (68)” | “28 (70)” | “30 (75)” | “31 (78)” | “37 (93)” | “34 (85)” |

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.8.5-2"></a>

##### Severity of adverse events

> “Among subjects receiving VK2735, the majority (98%) of reported drug-related treatment-emergent adverse events (TEAEs) were categorized as mild or moderate in severity. The majority (99%) of TEAEs that were GI in nature were also reported as mild or moderate.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “There were no Grade 4/5 (life-threatening/death) drug-related TEAEs.”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.8.5-3"></a>

##### Serious adverse events

> “Three participants (pts) had drug-related SAEs: 1 pt with angioedema/urticaria in the 60 mg tx group; 1 pt with dehydration and 2 pts with nausea/vomiting in the 120 mg tx group. None led to withdrawal from study.”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.8.5-4"></a>

##### Pooled nausea and vomiting rates, VK2735 versus placebo

> “Nausea was reported among 58% of participants receiving VK2735 compared with 48% for placebo. Among subjects receiving VK2735, the majority (99%) of reported nausea was characterized as mild or moderate. Vomiting was reported in 26% of VK2735-treated subjects compared with 10% among subjects receiving placebo.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-3.1.6.8.5-5"></a>

##### Common drug-related gastrointestinal adverse events by dose

| Event, number of participants reporting (%) | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Gastroesophageal reflux disease | “0 (0%)” | “3 (8%)” | “0 (0%)” | “2 (5%)” | “1 (3%)” | “3 (8%)” |
| Nausea, mild | “16 (40%)” | “12 (30%)” | “15 (38%)” | “13 (33%)” | “22 (55%)” | “15 (38%)” |
| Nausea, moderate | “3 (8%)” | “2 (5%)” | “7 (18%)” | “8 (20%)” | “7 (18%)” | “7 (18%)” |
| Nausea, severe | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “2 (5%)” |
| Vomiting | “4 (10%)” | “2 (5%)” | “6 (15%)” | “8 (20%)” | “14 (35%)” | “14 (35%)” |
| Abdominal pain | “1 (3%)” | “1 (3%)” | “2 (5%)” | “1 (3%)” | “1 (3%)” | “2 (5%)” |
| Diarrhea | “5 (13%)” | “2 (5%)” | “3 (8%)” | “6 (15%)” | “6 (15%)” | “10 (25%)” |
| Constipation | “9 (23%)” | “9 (23%)” | “8 (20%)” | “12 (30%)” | “17 (43%)” | “11 (28%)” |

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.6.8.5-6"></a>

##### Drug-related gastrointestinal adverse events by severity grade

| Severity | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Any drug-related GI TEAE, mild, grade 1, n (%) | “17 (43)” | “18 (45)” | “16 (40)” | “18 (45)” | “21 (53)” | “18 (45)” |
| Any drug-related GI TEAE, moderate, grade 2, n (%) | “6 (15)” | “6 (15)” | “11 (28)” | “12 (30)” | “13 (33)” | “11 (28)” |
| Any drug-related GI TEAE, severe, grade 3, n (%) | “1 (3)” | “0” | “0” | “0” | “0” | “2 (5)” |
| Nausea, mild/moderate/severe, % of participants | “40/8/0” | “30/5/0” | “38/18/0” | “33/20/0” | “55/18/0” | “38/18/5” |
| Constipation, mild/moderate/severe, % of participants | “13/10/0” | “13/10/0” | “10/10/0” | “20/10/0” | “33/10/0” | “25/3/0” |
| Vomiting, mild/moderate/severe, % of participants | “3/8/0” | “5/0/0” | “8/8/0” | “18/3/0” | “30/5/0” | “15/15/5” |
| Diarrhea, mild/moderate/severe, % of participants | “10/0/3” | “5/0/0” | “8/0/0” | “15/0/0” | “10/5/0” | “15/10/0” |

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-3.1.6.8.5-7"></a>

##### Time course of gastrointestinal adverse events

> “GI-related adverse events were generally observed early in treatment, with decreasing frequency upon repeat dosing. Across the combined study arms, the weekly rates of nausea or vomiting did not exceed 5% at any point after the third week of treatment.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

> “It is important to note, though, even with this accelerated titration rate that the incidence of nausea, vomiting, constipation, diarrhea dropped off precipitously after the third week. Really, from week one to week two, precipitously. There was a little bit of a bump up in week three as that was the first titration step, but subsequent weeks, even with an up-titration, did not show an increase in any GI adverse events.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="topic-3.1.6.8.5-8"></a>

##### Placebo adverse event rates and the company's interpretation

> “I think it's important to note the placebo rates were also higher than we saw in the earlier study.”
> “I think that another contributor could be the relatively rapid titration rates we had here. The phase I suggested we could titrate quickly. We did titrate quickly.”
> “No, I don't think it's anything related to other components of the tablet.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="topic-3.1.6.8.5-9"></a>

##### Titration rate and gastrointestinal tolerability

> “Doses ≤60 mg similar to placebo; titration rate likely to impact GI profile”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “Dose escalation in 30 mg increments enabled rapid progression to higher dose levels with an encouraging tolerability profile, and gastrointestinal events diminished over time. Lower starting doses and longer titration windows may further improve tolerability.”

Source: [Viking Therapeutics ECO 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-05-12-Viking-Therapeutics-Presents-Data-from-its-13-Week-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-at-European-Congress-on-Obesity-ECO-2026)

> “I think in future studies, we'd probably start a little lower and extend the titration block to four weeks. Most of the treatment emergent adverse events that led to discontinuation were GI related.”

Source: [Viking Therapeutics Jefferies London conference transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/412049-jefferies-london-healthcare-conference-2025/)

<a id="topic-3.1.6.8.5-10"></a>

##### Exploratory maintenance cohort adverse events

> “The 90 mg to 30 mg was titrated a little more rapidly than the flat 90 mg, but the adverse event profile was pretty similar.”
> “On the last one, we do not have the cohort-by-cohort AE time course.”

Source: [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/)

<a id="topic-3.1.6.8.5-11"></a>

##### Laboratory values, vital signs, and heart rate

No evidence found.

<a id="heading-3.1.6.9"></a>

### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

#### Summary: limitations of the VENTURE-Oral Dosing evidence

Treatment lasted 13 weeks, and about 40 participants were randomized to each of 7 arms (280 in total). The release reports that weight loss showed “no plateau” at 13 weeks, so the maximal effect of each dose is not known from these data; FDA draft guidance asks that phase 2 duration capture “maximal or near-maximal” effects and sets its efficacy benchmark after 1 year of treatment. Week 16 off-treatment values were reported only for placebo and the 30, 60, and 90 mg arms.

Results are available only in company press releases, a sponsor-funded congress poster, a corporate presentation, and investor call transcripts. No peer-reviewed publication was identified, and the registry record has no posted results. Pharmacokinetic results, a stated objective, have not been reported. No document describes the sample size calculation, control of multiplicity, the estimand, or the handling of missing data.

Treatment discontinuation was 18% with placebo and ranged from 20% (15 mg and 30 mg) to 38% (120 mg) across the fixed-dose arms; discontinuation of treatment due to a TEAE was 13% with placebo and 30% with 120 mg. The release describes discontinuation due to adverse events as “low and well-balanced”. Its pooled VK2735 rates (28% for any treatment discontinuation and 20% for discontinuation due to an adverse event) are higher than the totals of the 5 fixed-dose arms in the per-arm tables (52 of 200, 26%, and 34 of 200, 17%); no document states whether the pooled rates include the exploratory maintenance cohort, whose disposition and adverse events are reported only as qualitative statements on the investor call. Efficacy was analyzed in a modified population that required a post-baseline weight, with 38 or 39 participants in the 60, 90, and 120 mg arms.

The fixed-dose arms were titrated in 2-week steps starting at 30 mg, every participant took 4 tablets daily after an overnight fast, and no food-effect study had been done. The doses later chosen for the phase 3 SUNRISE trials (27.5, 35, and 55 mg) were not tested as fixed arms. Nausea was reported by 48% of placebo recipients, and the company noted on its investor call that placebo adverse event rates were higher than in the earlier study. Participants with diabetes were excluded, all 15 sites were in the United States, and most participants were White, non-Hispanic, and female.

The documents differ on some points. The ECO release names the poster's trial the “VENTURE-2 Study” and calls the study “Phase 2a”. A corporate presentation note states “Baseline BMI ≥30 in all subjects” although eligibility allowed a BMI of 27 kg/m2 or higher with a comorbidity. The poster footnote on serious adverse events states “Three participants” and then lists one participant in the 60 mg arm and “1 pt with dehydration and 2 pts with nausea/vomiting” in the 120 mg arm. A third-party transcript of a November 2025 presentation records the maintenance cohort ending at 8.2% weight loss, while the release reports 9.2%. The registry arms are labeled “Dose #1” to “Dose #6” without the doses.

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055); [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity); [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf); [Viking Therapeutics ECO 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-05-12-Viking-Therapeutics-Presents-Data-from-its-13-Week-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-at-European-Congress-on-Obesity-ECO-2026); [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf); [Viking Therapeutics VENTURE-Oral topline call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/377050-study-result/); [Viking Therapeutics third quarter 2025 earnings call transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/366279-q3-2025/); [Viking Therapeutics Jefferies London conference transcript (2025)](https://stockanalysis.com/stocks/vktx/transcripts/412049-jefferies-london-healthcare-conference-2025/); [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download); [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
